Since the first enzyme immunoassays (EIA) for blood donor screening and laboratory diagnosis of human immunodeficiency virus (HIV) infection were licensed over 15 years ago, the quality of these tests has been continuously improved by the use of recombinant antigens and synthetic peptides (second test generation) and the sandwich EIA technology (third test generation) (10, 36). There is however a residual risk for false-negative results. The potential causes include the diagnostic window in the preseroconversion phase, genetic variability, atypical seroconversions, a delayed or absent immune re-
Since the first enzyme immunoassays (EIA) for blood donor screening and laboratory diagnosis of human immunodeficiency virus (HIV) infection were licensed over 15 years ago, the quality of these tests has been continuously improved by the use of recombinant antigens and synthetic peptides (second test generation) and the sandwich EIA technology (third test generation) (10, 36) . There is however a residual risk for false-negative results. The potential causes include the diagnostic window in the preseroconversion phase, genetic variability, atypical seroconversions, a delayed or absent immune response in the very early or advanced stages of infection, respectively, and laboratory reporting errors (6) .
The highest risk (Ͼ90%) of a false-negative result is observed in the preseroconversion phase during primary HIV infection (diagnostic window) (6) . The residual risk of an HIV infection by a seronegative blood donor during acute HIV infection is estimated to be 1/493,000 to 1/1,866,000 per transfused unit in healthy, unpaid donors in the United States and Germany (2) . In emergency department patients and in highrisk groups, it ranges between 0.14 and 0.17% (9, 18) .
Early detection of HIV infection is important for reasons of infection security, prevention, and individual prognosis. An antiretroviral combination therapy during primary HIV infection reduces the likelihood of a rapid progression to the AIDS stage. Moreover, the frequency of opportunistic infections, skin and mucous membrane diseases, and respiratory infections is reduced (4) .
Nucleic acid amplification technology (NAT) and HIV antigen (Ag) detection make it possible to reduce the residual risk of HIV transmission by blood and blood products and to improve the early detection of primary HIV infection in highrisk groups. With NAT testing, the diagnostic window (about 21 days) is reduced by 11 days and the residual risk is reduced by over 50% (2) . In the primary HIV infection, a localized viral replication (eclipse) takes place first and lasts for approximately 10 days. In exceptional cases, it can last for many months. Experiments conducted with the animal model indicate that the HIV-infected subject is not infectious during this phase of the incubation period. In the subsequent viremic phase, HIV RNA is the first and only detectable virus-specific marker for 1 to 5 days. In theory, all potentially infectious viral carriers are excluded by using the NAT technique, because no infectivity is observed during primary infection in the animal model before appearance of HIV type 1 (HIV-1) RNA (22) . The advantages of NAT are offset by its technical limitations. The automated processing of large numbers of samples, especially nucleic acid extraction, is not possible at this time or is possible only with limitations. HIV-1 RNA amplification is currently performed on pooled samples from donors in European blood banks as a cost-effective alternative to single-sample testing (25) . Depending on the pool size and detection threshold of NAT, the gain in sensitivity may be relatively low in comparison to HIV p24 Ag testing (17) . However, NAT testing of pools is more cost-effective than Ag determination in individual donations (24) .
Fourth-generation HIV screening assays that make combined HIV Ag and antibody detection possible in one test batch have been licensed in Europe since 1997 (12, 19, 20, 23, 26, (30) (31) (32) (33) (34) (35) . These combined assays offer the advantage of early detection of HIV infection via p24 Ag detection at a technical burden and financial cost more or less equal to those for HIV antibody testing using third-generation EIAs. The diagnostic window is reduced by 4 to 5 days compared with that for antibody detection alone (third-generation assays).
Approximately one-third of the solid phase is coated with monoclonal antibodies for HIV p24 Ag detection. The remaining binding capacity is available for antibody detection (sandwich or indirect EIA). Generally, fourth-generation assays exhibit a relatively high limit for detection of the HIV Ag module (Ͼ30 pg of p24 Ag/ml). For this reason, they cannot replace single-Ag determination with sensitive commercially available EIAs (detection limit: 3 to 5 pg/ml) (34) . The risk of interference is potentially higher with the HIV combined assays than with single-Ag or -antibody EIAs, since both serological markers are determined in one test batch. The specificity for blood donor screening (99.6 to 99.8%) is lower than that of thirdgeneration HIV EIAs (12, 19) . The higher rate of false-positive results (0.2%) of HIV combined assays has a particularly negative effect in cases of high sample throughput and low prevalence as in blood donor screening mainly because a separate Ag detection must be carried out in addition to the antibody confirmatory assay (Western blotting) in order to rule out an HIV infection (12) .
MATERIALS AND METHODS
Recently, new fourth-generation assays with an improved sensitivity of the Ag detection module and optimized specificity have been established. In a multicenter study (Table 1 shows a list of the participants), the new automated Cobas  Core HIV Combi EIA was compared to different fourth-and third-generation  HIV screening assays, p24 Ag tests, and HIV-1 reverse transcriptase PCR (RT-PCR) .
Cobas Core HIV Combi EIA. Cobas Core HIV Combi EIA is a double-Ag immunoassay for the detection of total antibodies to HIV-1 (including group O) and HIV-2, combined with a sandwich assay for the detection of HIV-1 p24 Ag. HIV-specific antibodies and the HIV-1 p24 Ag are detected within one determination.
Samples, digoxigenin-conjugated anti-p24 antibodies, and digoxigenin-conjugated RT were incubated with polystyrene beads coated with recombinant Ags derived from the Pol and Env regions of HIV-1 and HIV-2 as well as monoclonal antibodies against HIV-1 p24 Ag.
For Ag detection, HIV-1 p24 Ag reacted simultaneously with the anti-p24 antibodies on the bead and with the digoxigenin-labeled anti-p24 antibodies to form a sandwich complex.
For antibody detection, antibodies directed to RT formed a complex with immobilized Ag on the bead and digoxigenin-labeled Ag. Antibodies directed to HIV-1 Env Ag (including group O) and HIV-2 bound to the immobilized Ags. After beads were washed, the Env-specific antibodies were detected by incubation with recombinant Ags from the Env regions of HIV-1 and HIV-2 conjugated to horseradish peroxidase and a peroxidase-labeled antidigoxigenin monoclonal antibody.
After a second washing step, the bead was incubated with Cobas Core substrate. The intensity of the resulting color was roughly proportional to the amount of anti-HIV antibodies and HIV-1 p24 Ag detected in the specimen.
The cutoff was calculated from the following formula: 0.12 ϫ positive control ϩ negative control. A result was considered negative if the index value (signal sample/cutoff value) was Ͻ0.9. A sample is positive if its index value is Ն1.0. The grey zone ranges between index values Ն0.9 and Ͻ1.0.
Alternative HIV screening assays. Cobas Core HIV Combi EIA was compared to different third-and fourth-generation assays established as routine methods in the different centers participating at the study. Table 2 ). The detection limits of the PCR protocol employed for panels BCP 9010 to 9034 and ANT 6240 to 6248 were 50 and 400 copies of HIV-1 RNA/ml of plasma, respectively. All seroconversion samples were tested by Western blotting. HIV Ag detection (HIV-1 AG Monoclonal A) was performed for all the seroconversion panels with the exception of SIIDC35.
(ii) Single serum samples (n ϭ 32) from the acute phase of infection after seroconversion were obtained. mens were comparatively tested with Cobas Core HIV Combi EIA and alternative assays (see Table 3 ): (i) 7,579 unselected samples from blood donors from different blood transfusion centers, (ii) 303 unselected daily routine samples, (iii) 420 unselected specimens from hospitalized patients, (iv) 577 selected samples from hospitalized patients tested negative for acute or chronic hepatitis B, (v) a high number of potentially interfering samples (n ϭ 1,222) including rheumatoid factor-, anti-hepatitis C virus-, and human T-cell leukemia virus-positive serum samples, sera from patients suffering from acute viral, bacterial, and fungal infections, liver cirrhosis, or autoimmune diseases, dialysis patients, and pregnant women. Data evaluation and statistical analysis. Determinations were carried out in single measurements. Initially reactive (IR) specimens and discrepant specimens were repeated in single measurements or double determinations if enough sample material was available. Repeatedly reactive (RR) and discrepant samples were subjected to antibody and/or Ag confirmation with Western blotting and/or a single-Ag assay.
The performance of Cobas Core HIV Combi EIA was compared with that of alternative screening assays and HIV Ag and HIV-1 RNA detection for the seroconversion panels. The mean number of days by which the diagnostic window period was reduced with Cobas Core HIV Combi EIA in comparison to results for alternative third-and fourth-generation assays was calculated. The statistical significance of the reduction for each test was determined by using the Wilcoxon test for matched pairs (5) .
The time delay between blood sampling points in commercially available seroconversion panels used for the present study is on average relatively short (2 to 7 days) but may last up to 37 days, for example, for panel BBI W. The calculation model for time delays between assays established by the Paul Ehrlich Institute (11) was used. This method considers that seroconversion is theoretically possible the following day after the last negative follow-up sample. The total number and the average number of days of time delay for the 94 panels were compared with those for the most sensitive assay.
For the calculation of sensitivity and specificity, samples were considered HIV-1 positive if any of the following tests were positive: Western blotting (interpreted according to CDC criteria [7] ), HIV-1 p24 Ag assay, and HIV-1 RNA assay. Patients were considered HIV negative if all the screening assays were negative or, for the EIA reactive samples, if the Western blotting result was negative or indeterminate and the HIV-1 p24 Ag assay was negative. Table 2 ). Cobas Core HIV Combi detected HIV-1 primary infection one or more bleedings earlier in four seroconversions.
RESULTS

HIV
Cobas Core HIV Combi EIA was more sensitive than the alternative fourth-generation assays for early detection of HIV infection. HIV Ag was detected earlier in 2 of 16, 6 of 15, and 21 of 29 seroconversion panels than with VIDAS HIV DUO, Enzymun-Test HIV Combi, and Enzygnost HIV Integral, respectively (Table 2 ). In panel BCP 9029, Enzygnost HIV Integral was transiently positive on day 16 and remained negative until the end of follow-up. Since this sample was HIV-1 RT-PCR, HIV Ag, and Western blotting negative, the result should be considered false positive. Primary HIV infection was detected one or more bleedings earlier than with AxSYM HIV-1/2 gO, Prism HIV-Oplus, Enzygnost Anti-HIV1/2 Plus, and Genscreen HIV1/2, version 2, in 49 of 62, 25 of 36, 34 of 40, and 20 of 31 seroconversion panels, respectively. Conversely, seroconversion was detected one bleeding earlier with one or more third-generation assays in panels BCP 9017 and 9032 and NABI SVO-0251-1. A second diagnostic window with Cobas Core HIV Combi EIA was observed in three seroconversion panels. A borderline result (index value, 0.92) was observed on day 45 in BCP 9010. Cobas Core HIV Combi EIA became negative in panel SIIDC13 on day 50 when antigenemia was no longer detectable; this sample reacted weakly in the IMx HIV-1/HIV-2 III Plus and was tested negative with Enzygnost Anti-HIV1/2 Plus. Cobas Core HIV Combi EIA was borderline reactive (index values on duplicate testing: 0.87 and 0.92) in a follow-up sample obtained 4 days later that was positive in the third-generation assays. A borderline result was observed in the second follow-up sample of SIIDC35 with Cobas Core HIV Combi. In panel BCP 9012, the HIV-1 RNA copy number was transiently under the detection limit of HIV-1 RT-PCR (day 2). The viral load was below the detection limit in panel BCP 9014 in the last four follow-up samples (days 12 to 31).
The mean time delay of Cobas Core HIV Combi EIA (last negative sample plus 1 day) in comparison to HIV-1 RT PCR for 87 panels tested with both methods was 2.75 days. The difference in sensitivity between Cobas Core HIV Combi EIA and HIV-1 RT-PCR was statistically significant (P Ͻ 0.0001). Table 3 gives an overview of the mean time delays obtained for Cobas Core HIV Combi EIA and alternative assays in comparison to PCR for seroconversion panels. Cobas Core HIV Combi EIA showed a significantly higher sensitivity for the detection of primary HIV infection than alternative fourthgeneration (with the exception of VIDAS HIV DUO) and third-generation assays (P Ͻ 0.05) ( Table 3) .
All the 32 single-serum samples obtained during seroconversion were tested positive with Cobas Core HIV Combi EIA. A variable number of samples gave false-negative results with third-generation EIAs (Table 4) .
All 368 HIV-1 group M subtypes and group O and five samples positive for SIV-1 or -3 were found positive with Cobas Core HIV Combi EIA and the alternative assays. Only one sample (putative HIV-1 subtype S) was negative with Enzygnost Anti-HIV1/2 Plus and positive with Cobas Core HIV Combi EIA.
All the 302 sera from HIV-2-infected individuals, 3 SIV-2-positive sera from monkeys, and subtyped samples from BBI panel WWRB301 (M) (n ϭ 47) and AfrRB1 (n ϭ 42) were tested positive with Cobas Core HIV Combi EIA and the alternative assays (Table 4) . One HIV-2-positive serum sample from Guinea-Bissau gave an index value (1.16) close to the cutoff with Cobas Core HIV Combi EIA and Enzygnost Anti-HIV1/2 Plus.
All the cell culture supernatants (n ϭ 62) infected with different HIV-1 subtypes, including group M subtypes A to H, group O, HIV-2, and unknown subtypes were detected with a twofold-to more-than-fivefold-higher sensitivity with Cobas Core HIV Combi EIA than with Enzymun-Test HIV Combi (data not shown (Table 4 ). The Ampliscreen test was performed for 7 of the 11 RR samples from blood donors; all 7 were HIV-1 RNA negative. Cobas Core HIV Combi EIA allowed a high discrimination between negative and positive samples, since samples from only 3 of 7,579 blood donors gave an initially borderline reaction (index values: 0.9 to 1.0). The specificity of Cobas Core HIV Combi EIA for blood donors was high: 99.84% for IR samples and 99.85% for RR samples. The specificity of Enzygnost Anti-HIV-1/2 Plus was 99.83% (IR and RR samples). Prism Anti-HIV 1/2 showed 99.80% specificity for IR samples and 99.83% specificity for RR samples.
One hemolytic sample of 303 unselected routine sera was RR in the Cobas Core HIV Combi EIA but negative in the alternative assays, Western blotting and HIV p24 Ag EIA (Table 4 ). In a group of 420 unselected hospitalized patients with an extremely high prevalence of HIV, 50 HIV-positive confirmed samples were found with Cobas Core HIV Combi EIA and Enzymun-Test HIV Combi (Table 4) . Three RR samples were Western blot indeterminate and HIV Ag negative. No follow-up sera were available, and samples were excluded from specificity analysis. One sample was initially negative in the Cobas Core HIV Combi EIA but positive in the Enzymun-Test HIV Combi. The sample was positive on repeated testing. Western blotting was indeterminate (gp160 reactive), and the sample was HIV Ag negative. This result was excluded from specificity analysis since no follow-up sample was available.
Fourteen false-positive results were obtained in the collec- Table 4) . Most of the false positives (n ϭ 5) were among the group of hepatitis A virus (HAV)-immunoglobulin M (IgM)-positive sera. Two sera each from pregnant women and human T-cell leukemia virus-infected patients and one sample each from dialysis patients, patients with autoimmune diseases or chronic hepatitis B virus infection, Toxoplasma gondii IgG-positive individuals, and one person vaccinated against influenza virus were also false positive. Cobas Core HIV Combi EIA showed a sensitivity of 100% for HIV-1-and HIV-2-positive samples (Table 5) . Overall, 30 RR false-positive results out of 10,031 HIV-negative samples, including a high number of potentially cross-reactive specimens, were obtained with Cobas Core HIV Combi EIA (Table  4) . It is to be expected that about 1 of 334 specimens analyzed will be incorrectly identified as false positive. The specificity of Cobas Core HIV Combi EIA was 99.73% (Table 5) . In most cases, the total number of samples measured with each one of the alternative assays was too low to get a statistically reliable result for specificity (Table 4) .
DISCUSSION
The results of our study demonstrate that Cobas Core HIV Combi EIA permits an earlier diagnosis of HIV infection than third-generation EIAs. The time delay in comparison to HIV-1 RNA amplification is about 2.7 days (Table 3) . By using fourthgeneration assays with a more sensitive HIV Ag detection module (detection limit, Յ10 pg of p24 Ag/ml), such as Cobas Core HIV Combi EIA, the diagnostic window is reduced by about 1.5 to 2.5 days in comparison to that for less-sensitive combined p24 Ag and antibody assays (detection limit, Ն30 pg of p24 Ag/ml). As shown by the results obtained with Coulter HIV p24 Ag assay, the diagnostic window would be reduced by a further 0.5 days with a lower detection limit of the Ag module (Table 3) . Of note, the new VIDAS Duo Ultra, with a detection limit of 3 pg of p24 Ag/ml (20) , not investigated here, shows a sensitivity which is equal to that of one of the most sensitive HIV p24 Ag assays (detection limit, 2.2 pg of p24 Ag/ml) available on the market (32) .
The diagnostic window would be reduced by 2.7 days in comparison to that for Cobas Core HIV Combi EIA by amplification of HIV-1 RNA by RT-PCR from plasma or serum The prevalence of HIV-1 group M non-B subtypes (subtypes A and C to J) and HIV-2 infections is increasing relatively quickly in Europe. HIV-1 group O infections remain a rarity. The epidemiological significance of HIV-1 group N, described only recently, is not yet known (28) . The genetic variability represents a challenge in particular for the early detection of HIV infection. In the seroconversion phase, false-negative results and delayed detection of antibody response are observed in infections with HIV-1 non-B subtypes and HIV-2 (1, 8) . In recent years, the sensitivity for detection of HIV-1 non-B subtypes has been optimized. However, obtaining seroconversion samples with HIV-1 non-B subtypes in order to permit an extensive evaluation of the sensitivities of newly developed tests is difficult. In the present evaluation, one seroconversion from a patient with HIV-1 subtype E infection (SIIDC24) was tested with Cobas Core HIV Combi EIA and HIV-1 AG Monoclonal A. Both assays were highly reactive in the first blood sample obtained 7 days after onset of symptoms. Tersmette et al. (29) reported the failure of a monoclonal antibody to detect p24 Ag from certain strains of HIV. HIV-1 subtype O, which is highly divergent from other HIV-1 subtypes known so far (13), may not be detected by assays using monoclonal antibodies for the capture of p24 Ag. Our results from dilution series of cell supernatants infected with different HIV-1 subtypes, including HIV-1 group O isolates and HIV-2, show that no commercially available assay (HIV p24 Ag EIA or fourthgeneration EIA) is capable of detecting every HIV-1 virus lysate with an optimal sensitivity. Although a limited number of lysates were tested, Cobas Core HIV Combi EIA was likely to have a higher sensitivity for HIV-2 Ag detection than the Coulter HIV p24 Ag assay. Previous studies reported a variable sensitivity of fourth-generation assays for HIV-1 group M non-B subtypes and HIV-2 (12, 20, 33) .
There is a potential risk for false-negative results due to the absence of p24 Ag in the Ag mixture of Cobas Core HIV Combi. In general, anti-p24 antibodies are, together with antienvelope antibodies, the first to appear during seroconversion (21) . HIV RT has been included in analogy to EnzymunTest HIV Combi in the antigenic mixture of Cobas Core HIV Combi EIA in order to avoid false-negative results in the early seroconversion phase after disappearance of HIV antigenemia since p24 Ag would have interfered with anti-p24 for HIV Ag capture. As shown by the results of our study, in only 3 of 94 seroconversions were transient borderline-negative results measured with Cobas Core HIV Combi EIA in the early phase of seroconversion; this effect was also observed with EnzymunTest HIV Combi in a former study (12) and could therefore possibly result from the absence of anti-p24 detection. The second reason for including RT as the Ag in the Cobas Core HIV Combi EIA is that, with gp41 alone, the sensitivity of the assay would have been impaired not only during seroconversion but also at all stages of the disease. The RT is highly conserved among HIV-1 group M and O isolates and HIV-2 and induces a cross-reactive, predominantly IgG response (W. Melchior, unpublished data).
A second diagnostic window may be observed not only in serological assays, since, in two cases of primary infection, the viral load decreased to under the detection limit of 50 copies of HIV-1 RNA/ml of plasma for HIV-1 RT-PCR after initially positive results. In panel BCP 9014 HIV-1 RNA was not detectable from day 12 (fourth follow-up sample) until the end of follow-up (day 31, seventh follow-up sample). With NAT, false-negative results are observed in infected subjects with a low viral load independent of HIV-1 subtype and stage of disease (3) .
A second potential risk for impaired sensitivity is that a more limited area of the solid phase can be used for antibody detection since about one-third of the binding sites are occupied by anti-p24 antibody for HIV Ag detection. A time delay between third-generation assays and Cobas Core HIV Combi EIA was observed in three seroconversions with weak, delayed, or absent antigenemia. Gürtler et al. reported a delayed detection of primary infection with Enzymun-Test Combi in an HIV p24 Ag-negative seroconversion panel (12) .
Anti-HAV-IgM antibody-positive samples possibly can lead to elevated signals with Cobas Core HIV Combi EIA, since 5 out of 125 anti-HAV-IgM-positive samples were tested as false positives. This interference cannot be explained by cross-reactive epitopes of HIV RT and HAV polymerase since these enzymes are not related, but rather most probably by immune complex formation.
The risk of interference is potentially higher with the HIV combined assays than with single-Ag or -antibody EIAs, since both serological markers are determined in one test batch. The specificity for blood donor screening with licensed fourth-generation assays (99.6 to 99.8%) was lower than that of thirdgeneration HIV EIAs (12, 18) . The higher rate of false-positive results (0.2%) of HIV combined assays has a particularly negative effect in blood donor screening, where a high sample throughput and low prevalence are to be expected, because a higher number of donations must be withdrawn and a separate Ag detection in addition to the antibody confirmatory assay (Western blotting) must be carried out in order to rule out an HIV infection. The specificities of the new Cobas Core HIV Combi EIA for 7,579 blood donors (99.84%) and for more than 10,000 samples (99.73%), including potentially interfering sera, were very high. Cobas Core HIV Combi EIA showed a better performance than Enzymun-Test HIV Combi, which achieved a specificity of 99.60% in 7,659 negative samples (12) . The specificity of Cobas Core HIV Combi EIA was equivalent to that of third-generation assays, such as Enzygnost Anti-HIV1/2 Plus and Prism HIV-O Plus, which are routinely used for blood donor screening. Our results show that fourth-generation assays with improved specificity are suitable for blood donor screening in terms of specificity. Furthermore they detect HIV p24 Ag with a sensitivity comparable to that of single-Ag assays. Cobas Core HIV Combi EIA may represent an alternative to separate Ag determination in the diagnostic lab- 
